Abstract
Demineralization and disorganized bone growth may result in children treated with diphosphonates.
Similar content being viewed by others
References
Bassett, C. A. L., et al.: Diphosphonates in the treatment of Myositis Ossificans. Lancet7627, 845 (1969)
Fleisch, H., Bonjour, J.-P.: Diphosphonate treatment in bone disease. New Engl. J. Med.,289, 1419 (1973)
Geho, W. B., Whiteside, J. A.: Experience with disodium etidronate in diseases of ectopic calcification. Clinical aspects of metabolic bone disease, 1972, p. 506–511, Editors Frame, B., Parfitt, A. M., and Duncan, H., Amsterdam: Excerpta Medica 1973
Jowsey, J., Holley, K. E., Linman, J. W.: Effect of sodium etidronate in adult cats. J. Lab. clin. Med.76, 126 (1970)
King, W. R., Francis, M. D., Michael, W. R.: Effect of disodium ethane-1-hydroxy-1, 1 diphosphonate on bone formation. Clin. Orthop.78, 251 (1971)
Russell, R. G. G., Smith, R.: Diphosphonates — Experimental and clinical aspects. J. Bone Jt Surg.55 B, 66 (1973)
Smith, R., Russell, R. G. G., Woods, C. G.: Myositis ossificans progressiva, clinical features of 8 patients and their response to treatment. J. Bone Jt Surg.58 B, 48 (1976)
The Procter and Gamble Company: Unpublished data on file
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wood, B.J., Robinson, G.C., Andrew, C. et al. Drug induced bone changes in myositis ossificans progressiva. Pediatr Radiol 5, 40–43 (1976). https://doi.org/10.1007/BF00988661
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00988661